JP2015520172A - Ｄｌｌ−４に結合する抗原結合蛋白質 - Google Patents

Ｄｌｌ−４に結合する抗原結合蛋白質 Download PDF

Info

Publication number
JP2015520172A
JP2015520172A JP2015515116A JP2015515116A JP2015520172A JP 2015520172 A JP2015520172 A JP 2015520172A JP 2015515116 A JP2015515116 A JP 2015515116A JP 2015515116 A JP2015515116 A JP 2015515116A JP 2015520172 A JP2015520172 A JP 2015520172A
Authority
JP
Japan
Prior art keywords
seq
sequence number
chain
variable region
dll
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015515116A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015520172A5 (enExample
Inventor
エドウィージ・グロス
ヤンリアン・ジャン
ヘユー・ジョウ
ランディ・ギャストワート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sorrento Therapeutics Inc
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of JP2015520172A publication Critical patent/JP2015520172A/ja
Publication of JP2015520172A5 publication Critical patent/JP2015520172A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015515116A 2012-05-31 2013-05-28 Ｄｌｌ−４に結合する抗原結合蛋白質 Pending JP2015520172A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261654019P 2012-05-31 2012-05-31
US61/654,019 2012-05-31
PCT/US2013/042912 WO2014062245A2 (en) 2012-05-31 2013-05-28 Antigen binding proteins that bind dll-4

Publications (2)

Publication Number Publication Date
JP2015520172A true JP2015520172A (ja) 2015-07-16
JP2015520172A5 JP2015520172A5 (enExample) 2016-07-14

Family

ID=49670535

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015515116A Pending JP2015520172A (ja) 2012-05-31 2013-05-28 Ｄｌｌ−４に結合する抗原結合蛋白質

Country Status (7)

Country Link
US (2) US10174107B2 (enExample)
EP (1) EP2855523A4 (enExample)
JP (1) JP2015520172A (enExample)
CN (1) CN104603151A (enExample)
CA (1) CA2874979A1 (enExample)
HK (1) HK1206038A1 (enExample)
WO (1) WO2014062245A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3485908B1 (en) 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
HRP20190044T1 (hr) 2011-09-23 2019-02-22 Oncomed Pharmaceuticals, Inc. Agensi koji vežu vegf/dll4 i njihove uporabe
JP2015520172A (ja) 2012-05-31 2015-07-16 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｄｌｌ−４に結合する抗原結合蛋白質
KR20170029490A (ko) 2014-07-11 2017-03-15 제넨테크, 인크. 노치 경로 억제
MX382902B (es) 2014-10-31 2025-03-13 Oncomed Pharm Inc Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
AR105444A1 (es) 2015-07-22 2017-10-04 Sorrento Therapeutics Inc Anticuerpos terapéuticos que se unen a la proteína codificada por el gen de activación de linfocitos 3 (lag3)
WO2017053705A1 (en) 2015-09-23 2017-03-30 Oncomed Pharmaceuticals, Inc. Methods and compositions for treatment of cancer
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539384A (ja) * 2006-06-06 2009-11-19 ジェネンテック・インコーポレーテッド 抗ｄｌｌ４抗体および抗ｄｌｌ４抗体使用の方法
JP2010504755A (ja) * 2006-09-29 2010-02-18 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
JP2010512749A (ja) * 2006-12-14 2010-04-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトＤｅｌｔａ様リガンド４に対するヒト抗体
US20110117079A1 (en) * 2009-08-29 2011-05-19 Abbott Laboratories Therapeutic dll4 binding proteins
JP2012502650A (ja) * 2008-09-19 2012-02-02 メディミューン，エルエルシー Ｄｌｌ４に対する抗体およびその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275449B1 (en) * 2000-06-16 2016-09-28 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to BLyS
IL149820A0 (en) * 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US20070244709A1 (en) * 2006-04-17 2007-10-18 Earthworks Systems, Llc Methods of producing and recycling plastic cards
JP2015520172A (ja) 2012-05-31 2015-07-16 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｄｌｌ−４に結合する抗原結合蛋白質

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539384A (ja) * 2006-06-06 2009-11-19 ジェネンテック・インコーポレーテッド 抗ｄｌｌ４抗体および抗ｄｌｌ４抗体使用の方法
JP2010504755A (ja) * 2006-09-29 2010-02-18 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
JP2010512749A (ja) * 2006-12-14 2010-04-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトＤｅｌｔａ様リガンド４に対するヒト抗体
JP2012502650A (ja) * 2008-09-19 2012-02-02 メディミューン，エルエルシー Ｄｌｌ４に対する抗体およびその使用
US20110117079A1 (en) * 2009-08-29 2011-05-19 Abbott Laboratories Therapeutic dll4 binding proteins

Also Published As

Publication number Publication date
US10717779B2 (en) 2020-07-21
WO2014062245A3 (en) 2014-10-09
US20130323248A1 (en) 2013-12-05
WO2014062245A2 (en) 2014-04-24
CN104603151A (zh) 2015-05-06
CA2874979A1 (en) 2014-04-24
US20190169282A1 (en) 2019-06-06
HK1206038A1 (en) 2015-12-31
US10174107B2 (en) 2019-01-08
EP2855523A2 (en) 2015-04-08
EP2855523A4 (en) 2016-02-17

Similar Documents

Publication Publication Date Title
JP7140867B2 (ja) Ｐｄ－ｌ１に結合する抗原結合性タンパク質
JP7624573B2 (ja) Ｐｄ－１に結合する抗原結合蛋白質
JP6829330B2 (ja) Ｐｄ−ｌ１に結合する抗原結合蛋白質
US10717779B2 (en) Methods for blocking an interaction between notch-1 and delta-like 4 (DLL-4) by administering a DDL-4 antibody
JP6441792B2 (ja) Ｅｇｆｒに結合する抗原結合蛋白質
JP2015518827A5 (enExample)
JP6388576B2 (ja) Ｉｇｆ１ｒに結合する抗原結合タンパク質
JP2017529331A (ja) Ｃｘｃｒ３に結合する抗原結合タンパク質

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170314

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170613

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180502

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181002